00:00 Speaker a
CVS is the latest major name in healthcare to report revenue this season. Join me now and there are three key points from my previous healthcare revenue: senior health reporter Anjali Camlani. Now, let's break down some of these takeaways.
00:16 Anjali Camlani
Yeah, so um, obviously the healthcare sector is very big. Therefore, we will do sub-sector takeout. First, I would like to focus on the insurance sector. It's moving in a really different direction than what we've seen before. Medicare's advantage was a major theme last year, and it really puts a burden on businesses, but this year it wasn't that much of a factor. And we're watching United Health Care after it became a huge hit due to increased use. Others like CVS today and Humara yesterday say it's not such a hit. That's good news. This means that older people don't use as much health care as they need. Maybe they've just got out of the rush after its use. Therefore, costs need to be normalized there. Meanwhile, there are several exits in the ACA market, and companies advertise them. But of course, that's bad news for consumers. This is because the fewer options available in the market, the fewer options you have to choose your own insurance. And that's what we've seen other insurance companies like Oscar Health, which was a massive player on the ACA marketplace, and we're talking about seeing the need for more competition. Meanwhile we saw a shift a little further away from it. So if you want to hear what Oscar Health CEO Mark Bertolini said in the past, ask.
02:19 Mark Bertorini
We believe that the individual markets for all Americans can buy what they need and what they want to cover their healthcare costs is the way to go in the future. But I think that's the way we need to go. I think that's a newer version of healthcare for Americans compared to the 80-year-old version we live in now.
02:46 Anjali Camlani
The 80-year-old version is employer healthcare. So we are seeing a transition to what is known as ICRA. You won't get bored of the details, but there's a bit of innovation going on in that area. So what to think about the insurance sector about what will it come someday. Pharma, on the other hand, is that it's a big thing and we've talked about some of the few cuts in those biotech companies, but in fact it's the best thing with tariffs right now for these companies. Do you have any questions left? Does it increase the cost of drug pricing? Do hospitals actually increase costs? These are all things we're waiting to see, especially as medical device manufacturers were the most hit with existing tariffs. They are working on a carve out to see if it goes through or if they have to endure that pain for the rest of the year. Meanwhile, GLP-1 drops slightly there. This is interesting after compound interest is taken from the market. Thanks to the FDA removing these drugs from the shortage list. We've seen these deals like today's Novo Nordisk and CVS in that ceremony plan. So, the Wegovy you choose and want to have you choose Wegovy, a Novo Nordisk Drug over Eli Lilly, and wait for the pillform to come out, so it's like setting the market a little more competitive. And there's no news on what the cost prices will be. There are a lot of up and down movements as you can see. I would like to remind everyone that at the customs point, we have seen all of these major companies.
05:02 Speaker a
Okay. Well, we wait, if they're not, we're waiting. Of course, they are waiting for some exemptions, as some other industries are beginning to see, and some industries are still trying to get the ears of the president. Thank you very much, Anjali.
